Since a single-cell analysis study highlighted that CD19 is more expressed in brain pericytes than in lung pericytes (Parker et al., 2020), Kong et al. hypothesized that CD19 CAR-NK therapy could be employed in the treatment of glioblastoma. Here, CD19 is linked to glioblastoma.